Breaking News Instant updates and real-time market news.

IMGN

ImmunoGen

$12.10

-0.06 (-0.49%)

, MRK

Merck

$53.41

-0.71 (-1.31%)

08:14
03/25/18
03/25
08:14
03/25/18
08:14

ImmunoGen presents data from FORWARD II assessment of Mirvetuximab Soravtansine

ImmunoGen (IMGN) announced encouraging efficacy and favorable tolerability data from the FORWARD II cohort assessing mirvetuximab soravtansine in combination with Merck's (MRK) anti-PD-1 therapy pembrolizumab in patients with platinum-resistant epithelial ovarian cancer. In the subset of 8 patients with medium or high folate receptor alpha expression levels, the confirmed overall response rate was 63%, with a median progression-free survival of 8.6 months. For all patients, the confirmed ORR was 43%, with a median PFS of 5.2 months; patients in this cohort had received a median of 4.5 prior lines of systemic therapy, with 64% of patients receiving 4 or more prior lines. As previously reported, at full dosing, the combination of mirvetuximab and pembrolizumab demonstrates favorable tolerability, consistent with the known safety profiles of each agent, with primarily mild to moderate adverse events observed. Based on these data, ImmunoGen is enrolling an additional 35 patients with medium or high FRalpha expression levels in an expansion cohort in the FORWARD II study.

IMGN

ImmunoGen

$12.10

-0.06 (-0.49%)

MRK

Merck

$53.41

-0.71 (-1.31%)

  • 25

    Mar

  • 03

    Apr

  • 04

    Apr

  • 23

    Apr

  • 24

    Apr

  • 23

    Oct

IMGN ImmunoGen
$12.10

-0.06 (-0.49%)

01/31/18
HCWC
01/31/18
INITIATION
Target $18
HCWC
Buy
ImmunoGen initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay started ImmunoGen with a Buy rating and $18 price target. The analyst believes ADC's, a multi-component system involving a targeting antibody linked to cytotoxic agents, have a "significant and hitherto underappreciated role to play in the war against cancer." He believes ImmunoGen has a differentiated ADC platform.
01/31/18
01/31/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Lumentum (LITE) was initiated with a Buy at UBS while Oclaro (OCLR) was initiated with a Sell. 2. ImmunoGen (IMGN) initiated with a Buy at H.C. Wainwright. 3. Salesforce (CRM) and Workday (WDAY) were initiated with a Buy at Cleveland Research. 4. Cooper Tire (CTB) was initiated with a Buy at Longbow, while Goodyear Tire (GT) was initiated with a Neutral. 5. Acacia Communications (ACIA) initiated with a Buy at UBS. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/08/18
RBCM
02/08/18
INITIATION
Target $12
RBCM
Outperform
ImmunoGen assumed with an Outperform at RBC Capital
RBC Capital analyst Kennen MacKay assumed coverage of ImmunoGen with an Outperform rating and a price target of $9. MacKay notes "mirvetuximab's market opportunity in 2L+ platinum-resistant/refractory folate receptor alpha positive ovarian cancer", modeling potential $850M in peak risk-unadjusted sales. MacKay also points to the positive impact of U.S. tax changes and believes 2018 could be a "transformational year" with a scheduled futility analysis planned ahead of top-line data in the first half of 2019.
03/21/18
RBCM
03/21/18
NO CHANGE
Target $16
RBCM
Outperform
ImmunoGen price target raised to $16 from $12 at RBC Capital
RBC Capital analyst Kennen MacKay raised his price target on ImmunoGen to $16 and kept his Outperform rating. MacKay cites the Mirvetuximab combo opportunities as a potential catalyst ahead of the SGO data which he contends may provide initial indications of the combo's synergistic activity.
MRK Merck
$53.41

-0.71 (-1.31%)

03/02/18
LEER
03/02/18
NO CHANGE
Target $29
LEER
Outperform
Leerink ups Heron Therapeutics target to $29 after competitor setback
Leerink analyst Ami Fadia raised her price target for Heron Therapeutics (HRTX) to $29 from $27 after Tesaro (TSRO) announced earlier this week that it has withdrawn all promotional support for IV Varubi, based on numerous reports of anaphylaxis. Heron's Cinvanti, Tesaro's Varubi and Merck's (MRK) Emend are the only three branded NK-1 antagonists in the market today for chemo induced nausea and vomiting, Fadia tells investors in a research note. With Emend expected to go generic soon, Cinvanti will be the sole marketed branded agent, the analyst adds. She increased her 2023 estimate for Cinvanti from $150M to just under $200M and keeps an Outperform rating on Heron Therapeutics. The analyst continues to see upside for the stock ahead of the two Phase 3 trials for HTX-011 expected to read out in Q2.
03/12/18
LEER
03/12/18
UPGRADE
LEER
Outperform
Merck upgraded to Outperform from Market Perform at Leerink
03/12/18
LEER
03/12/18
UPGRADE
Target $66
LEER
Outperform
Leerink upgrades Merck to Outperform ahead of KN-189 presentation
Leerink analyst Seamus Fernandez upgraded Merck (MRK) to Outperform from Market Perform with an unchanged price target of $66. The shares closed Friday up 38c to $55.14. Keytruda will continue to dominate the first-line non-small cell lung cancer market, Fernandez tells investors in a research note. Following his firm's lung cancer survey, the analyst believes Merck will deliver upside to consensus Keytruda estimates along with positive earnings leverage in the second half of 2018 and 2019. He thinks KN-189 likely will show a clinically meaningful overall survival benefit for the Keytruda plus chemo combo in all patients, including a strong benefit in patients with moderate or low PD-L1 biomarker levels. Fernandez does not believe Bristol-Myers' (BMY) Opdivo and Yervoy combo will supplant Keytruda as the market leader. The analyst thinks now is the time to own shares of Merck.
03/12/18
03/12/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Time Warner (TWX) upgraded to Buy from Neutral at UBS with analyst John Hodulik saying while he expects the takeover by AT&T (T) to receive regulatory approval, he believes the current environment would make Time Warner's assets "highly attractive" to other media companies and Internet-based competitors were the deal to be blocked. 2. Carlyle Group (CG) and Apollo Global (APO) were upgraded to Buy from Neutral at Citi. 3. Merck (MRK) upgraded to Outperform from Market Perform at Leerink with analyst Seamus Fernandez saying Keytruda will continue to dominate the first-line non-small cell lung cancer market. 4. SAP (SAP) upgraded to Outperform from In Line at Evercore ISI with analyst Stewart Materne III saying that he believes the risk/reward is more attractive at current levels following the stock's 6% pullback. 5. Aratana Therapeutics (PETX) upgraded to Buy on valuation at CL King with the firm citing favorable risk/reward. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

PETQ

PetIQ

$28.26

1 (3.67%)

, PRSP

Perspecta

$21.64

-0.31 (-1.41%)

19:00
08/14/18
08/14
19:00
08/14/18
19:00
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: PetIQ…

PETQ

PetIQ

$28.26

1 (3.67%)

PRSP

Perspecta

$21.64

-0.31 (-1.41%)

FENG

Phoenix New Media

$4.12

-0.055 (-1.32%)

EGN

Energen

$73.15

1.76 (2.47%)

FANG

Diamondback Energy

$133.75

1.84 (1.39%)

ADNT

Adient

$42.65

0.19 (0.45%)

ERI

Eldorado Resorts

$43.85

0.55 (1.27%)

TEVA

Teva

$22.12

0.17 (0.77%)

CASA

Casa Systems

$15.62

-0.17 (-1.08%)

A

Agilent

$66.72

0.77 (1.17%)

CREE

Cree

$50.17

-0.11 (-0.22%)

VRAY

ViewRay

$9.89

-0.01 (-0.10%)

CRZO

Carrizo Oil & Gas

$24.31

0.62 (2.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 19

    Aug

  • 21

    Aug

  • 28

    Aug

  • 04

    Sep

  • 10

    Sep

  • 16

    Sep

  • 15

    Aug

  • 15

    Aug

AAP

Advance Auto Parts

$156.01

11.22 (7.75%)

18:47
08/14/18
08/14
18:47
08/14/18
18:47
Upgrade
Advance Auto Parts rating change  »

Advance Auto Parts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

SPHS

Sophiris Bio

$2.74

0.13 (4.98%)

18:37
08/14/18
08/14
18:37
08/14/18
18:37
Recommendations
Sophiris Bio analyst commentary  »

Sophiris Bio topsalycin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$52.87

0.65 (1.24%)

, GOOG

Alphabet

$1,241.95

6.85 (0.55%)

18:30
08/14/18
08/14
18:30
08/14/18
18:30
Hot Stocks
Verizon to partner with YouTube TV for 5G residential broadband package »

Verizon (VZ) announced it…

VZ

Verizon

$52.87

0.65 (1.24%)

GOOG

Alphabet

$1,241.95

6.85 (0.55%)

GOOGL

Alphabet Class A

$1,258.15

9.39 (0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 14

    Aug

  • 22

    Aug

  • 18

    Sep

  • 20

    Sep

  • 28

    Oct

NVDA

Nvidia

$261.47

5.39 (2.10%)

18:27
08/14/18
08/14
18:27
08/14/18
18:27
Upgrade
Nvidia rating change  »

Nvidia double-upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

ORCL

Oracle

$48.23

0.21 (0.44%)

, RMNI

Rimini Street

$6.01

0.11 (1.86%)

18:26
08/14/18
08/14
18:26
08/14/18
18:26
Hot Stocks
Court grants Oracle's motion for permanent injunction against Rimini Street »

For the second time, a…

ORCL

Oracle

$48.23

0.21 (0.44%)

RMNI

Rimini Street

$6.01

0.11 (1.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$261.47

5.39 (2.10%)

18:22
08/14/18
08/14
18:22
08/14/18
18:22
Upgrade
Nvidia rating change  »

Nvidia double-upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

CVS

CVS Health

$71.39

1.88 (2.70%)

18:20
08/14/18
08/14
18:20
08/14/18
18:20
Hot Stocks
CVS Health says 'actively working' with Ohio Managed Medicaid clients »

"CVS Health is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

VRAY

ViewRay

$9.89

-0.01 (-0.10%)

18:18
08/14/18
08/14
18:18
08/14/18
18:18
Syndicate
ViewRay $125M Spot Secondary; price range $9.25-$9.50 »

Morgan Stanley, Jefferies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 04

    Sep

CRZO

Carrizo Oil & Gas

$24.31

0.62 (2.62%)

18:16
08/14/18
08/14
18:16
08/14/18
18:16
Syndicate
Carrizo Oil & Gas 9.5M share Spot Secondary; price range $22.90-$23.50 »

Citi and Goldman Sachs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 15

    Aug

WTW

Weight Watchers

$77.39

1.8 (2.38%)

18:12
08/14/18
08/14
18:12
08/14/18
18:12
Syndicate
Weight Watchers 6M share Block Trade; price range $76.00-$77.00 »

Morgan Stanley is acting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERI

Eldorado Resorts

$43.85

0.55 (1.27%)

, PAY

Verifone

$23.00

-0.02 (-0.09%)

18:05
08/14/18
08/14
18:05
08/14/18
18:05
Hot Stocks
S&P announces changes to S&P MidCap 400 index »

S&P Dow Jones Indices…

ERI

Eldorado Resorts

$43.85

0.55 (1.27%)

PAY

Verifone

$23.00

-0.02 (-0.09%)

ADNT

Adient

$42.65

0.19 (0.45%)

DCT

DCT Industrial

$65.28

-0.34 (-0.52%)

PLD

Prologis

$64.05

-0.38 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$116.73

0.7 (0.60%)

18:00
08/14/18
08/14
18:00
08/14/18
18:00
Hot Stocks
Celanese to increase price of acetate flake by 50c/kg »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

GDDY

GoDaddy

$75.81

0.52 (0.69%)

17:43
08/14/18
08/14
17:43
08/14/18
17:43
Syndicate
GoDaddy files to sell 10,398,942 shares of Class A common stock »

Selling stockholders are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAG

MAG Silver

$8.64

0.07 (0.82%)

17:41
08/14/18
08/14
17:41
08/14/18
17:41
Earnings
MAG Silver reports Q2 EPS (3c), consensus (2c) »

Reports cash and cash…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$113.07

0.09 (0.08%)

17:39
08/14/18
08/14
17:39
08/14/18
17:39
Hot Stocks
SPDR Gold Trust holdings fall to 776.65MT from 784.60MT »

This is the 2nd…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNES

SenesTech

$0.95

-0.0779 (-7.60%)

17:36
08/14/18
08/14
17:36
08/14/18
17:36
Syndicate
Breaking Syndicate news story on SenesTech »

SenesTech files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MXWL

Maxwell

$3.98

0.59 (17.40%)

17:36
08/14/18
08/14
17:36
08/14/18
17:36
Hot Stocks
Breaking Hot Stocks news story on Maxwell »

VIEX Capital Advisors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEY

KeyCorp

$21.44

0.26 (1.23%)

, SYMC

Symantec

$18.66

-0.15 (-0.80%)

17:35
08/14/18
08/14
17:35
08/14/18
17:35
Hot Stocks
Appaloosa adds KeyCorp, exits NVIDIA »

David Tepper's…

KEY

KeyCorp

$21.44

0.26 (1.23%)

SYMC

Symantec

$18.66

-0.15 (-0.80%)

CFG

Citizens Financial

$40.39

0.54 (1.36%)

VST

Vistra Energy

$22.41

0.31 (1.40%)

EDU

New Oriental Education

$85.07

-0.08 (-0.09%)

QQQ

Invesco QQQ Trust

$181.44

1.1 (0.61%)

AMAT

Applied Materials

$48.38

0.12 (0.25%)

SMH

Market Vectors Semiconductor

$105.49

-0.25 (-0.24%)

ALL

Allstate

$98.35

0.2 (0.20%)

NVDA

Nvidia

$261.47

5.39 (2.10%)

MU

Micron

$50.62

-0.73 (-1.42%)

WDC

Western Digital

$64.98

0.75 (1.17%)

LNG

Cheniere Energy

$63.48

-0.13 (-0.20%)

WFC

Wells Fargo

$58.07

0.43 (0.75%)

PAH

Platform Specialty Products

$12.26

0.08 (0.66%)

BABA

Alibaba

$172.53

-5.12 (-2.88%)

NRG

NRG Energy

$32.83

0.33 (1.02%)

BAC

Bank of America

$30.80

0.33 (1.08%)

MGM

MGM Resorts

$28.99

-0.04 (-0.14%)

ALY

Allis-Chalmers

$0.00

(0.00%)

FB

Facebook

$181.11

1.03 (0.57%)

AGN

Allergan

$184.44

0.18 (0.10%)

GOOG

Alphabet

$1,241.95

6.85 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 14

    Aug

  • 16

    Aug

  • 16

    Aug

  • 22

    Aug

  • 23

    Aug

  • 05

    Sep

  • 10

    Sep

  • 11

    Sep

  • 12

    Sep

  • 18

    Sep

  • 20

    Sep

  • 27

    Sep

  • 01

    Oct

  • 18

    Oct

  • 19

    Oct

  • 28

    Oct

  • 30

    Oct

  • 12

    Apr

  • 13

    Jul

  • 15

    Oct

PETQ

PetIQ

$28.26

1 (3.67%)

17:33
08/14/18
08/14
17:33
08/14/18
17:33
Earnings
PetIQ reports Q2 adjusted EBITDA of $15.8M versus $7.6M in Q2 last year »

The company reported Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

TTNP

Titan Pharmaceuticals

$0.90

0.01 (1.12%)

17:33
08/14/18
08/14
17:33
08/14/18
17:33
Syndicate
Breaking Syndicate news story on Titan Pharmaceuticals »

Titan Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MHO

M/I Homes

$25.20

0.4 (1.61%)

17:32
08/14/18
08/14
17:32
08/14/18
17:32
Hot Stocks
M/I Homes approves $50M share repurchase program »

M/I Homes announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENPH

Enphase Energy

$5.05

-0.315 (-5.87%)

17:31
08/14/18
08/14
17:31
08/14/18
17:31
Syndicate
Breaking Syndicate news story on Enphase Energy »

Enphase Energy files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWGH

GWG Holdings

$7.55

-0.34 (-4.31%)

17:30
08/14/18
08/14
17:30
08/14/18
17:30
Hot Stocks
Breaking Hot Stocks news story on GWG Holdings »

GWG Holdings trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

GD

General Dynamics

$193.62

1.82 (0.95%)

17:29
08/14/18
08/14
17:29
08/14/18
17:29
Hot Stocks
General Dynamics awarded $147.7M U.S. Navy contract »

General Dynamics National…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.